Études psychédéliques Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE https://enseignements-2019.ehess.fr/2019/ue/2998/ Mardi de 18 h à 19 h 30 (amphithéâtre Rouelle, Muséum national d'Histoire naturelle, 57 rue Cuvier 75005 Paris), les 26 novembre, 17 décembre 2019, 28 janvier, 25 février, 31 mars, 28 avril, 26 mai et 30 juin 2020 Plan pour trouver l'amphi : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing NB : merci d'arriver en avance pour éviter de trouver portes closes. Le terme psychedelic a été forgé en 1956 par le psychiatre britannique Humphry Osmond (1917 - 2004) pour qualifier les effets psychiques de la mescaline et du LSD, deux substances psychotropes sur lesquelles [...]
Lire la suiteThe Philosophy of Psychedelic Transformation Chris Letheby Journal of Consciousness Studies. Introduction and Methodological Preliminaries Psychedelic drugs are remarkable substances which have been hailed as indispensable epistemic instruments for the sciences of mind, as unparalleled psychotherapeutic interventions, as unique sources of insight into the nature and genesis of psychosis and religion, and as keys to the survival and flourishing of the human species (Osmond 1957, Sessa 2012). After a politically driven decades long hiatus, scientific study of these drugs in humans has resumed with impressive results. Given the magnitude and variety of significance ascribed to the substances, it is surprising that philosophers have not [...]
Lire la suiteAustralia should be initiating a psychedelic research program : What are the barriers ? Nigel Strauss, Stephen J Bright and Martin L Williams Australian & New Zealand Journal of Psychiatry, 2016, Vol. 50, (11), 1036–1037 DOI: 10.1177/0004867416670520 A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that could be paradigm-changing for psychiatry (Nichols, 2016). These developments overturn a 30-year embargo on psychedelic research [...]
Lire la suitePsilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010 Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]
Lire la suitePatient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]
Lire la suiteLong-term use of psychedelic drugs is associated with differences in brain structure and personality in humans José Carlos Bouso, FernandaPalhano-Fontes, Antoni Rodríguez-Fornells, Sidarta Ribeiro, Rafael Sanches, José Alexandre S. Crippa, Jaime E.C. Hallak, Draulio B. de Araujo, Jordi Riba European Neuropsychopharmacology, 2015, 25, 483–492 http://dx.doi.org/10.1016/j.euroneuro.2015.01.008 Abstract Psychedelic agents have a long history of use by humans for their capacity to induce profound modifications in perception,emotion and cognitive processes. Despite increasing knowledge of the neural mechanisms involved in the acute effects of these drugs, the impact of sustained psychedelic use on the human brain remains largely unknown. Molecular pharmacology studies have shown that psychedelic 5-hydroxytryptamine (5HT)2A [...]
Lire la suiteSoigner l'alcoolisme et la dépression avec des psychédéliques? Entretien avec David Nutt #RTSsanté , 11 avril 2019 https://www.youtube.com/watch?time_continue=55&v=D8QNY2bdNCk&feature=emb_logo Vidéo en complément du reportage « Le retour des psychédéliques » : https://youtu.be/503cSLA0Z38 Parmi les très nombreux articles cosignés par le Professeur David J. NUTT, du Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom, les références suivantes sont disponibles sur le site du GRECC : Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. [...]
Lire la suiteBibliographie : Thérapeutiques psychédélique Dr Christian Sueur, GRECC, décembre 2019 Voir également : Bibliographie : LSD Bibliographie : Ayahuasca Bibliographie : Psilocybine Bibliographie : Kétamine Bibliographie : Salvia divinorum Bibliographie : Mescaline
Lire la suiteBIBLIOGRAPHIE : Psilocybes, psilocybine. Dr Christian SUEUR, GRECC, décembre 2019 Psilocybes, psilocybine : généralités ..............................1 Psilocybes : ethnologie ...................................................2 Psilocybine : clinique psychiatrique ..............................4 Psilocybine : pharmacologie ..........................................5 Psilocybine : toxicologie - "effets indésirables" .............7 Psilocybine : neurophysiologie ......................................9 Psilocybine : expériences mystiques .............................13 Psilocybine : thérapie psychédélique ............................15-19
Lire la suiteBIBLIOGRAPHIE : Substances psychédéliques : Pharmacologie, Neurophysiologie, Psychologie, Dr Christian SUEUR, GRECC, décembre 2019 Cf également : Bibliographie : Thérapies psychédéliques, Bibliographie : Substances psychédéliques, Culture, Spiritualité, Chamanisme Bibliographie : Psilocybine, Bibliographie : LSD, Bibliographie : Ayahuasca….
Lire la suite